Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) Operating Expenses (2016 - 2025)

ImmunityBio (IBRX) has disclosed Operating Expenses for 12 consecutive years, with $103.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Expenses rose 33.81% to $103.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $369.3 million, a 2.89% increase, with the full-year FY2025 number at $369.3 million, up 2.89% from a year prior.
  • Operating Expenses was $103.0 million for Q4 2025 at ImmunityBio, up from $87.7 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $111.9 million in Q1 2023 to a low of $77.0 million in Q4 2024.
  • A 5-year average of $88.7 million and a median of $86.3 million in 2021 define the central range for Operating Expenses.
  • Biggest YoY gain for Operating Expenses was 364.36% in 2021; the steepest drop was 50.41% in 2021.
  • ImmunityBio's Operating Expenses stood at $79.7 million in 2021, then increased by 6.66% to $85.0 million in 2022, then rose by 0.65% to $85.5 million in 2023, then fell by 10.03% to $77.0 million in 2024, then soared by 33.81% to $103.0 million in 2025.
  • Per Business Quant, the three most recent readings for IBRX's Operating Expenses are $103.0 million (Q4 2025), $87.7 million (Q3 2025), and $97.7 million (Q2 2025).